4D Molecular Therapeutics Inc FDMT

US Biotechnology

$14.47 ▼ -1.63% ($-0.24)

🔥 High Short Interest 🎢 High Beta

Open $14.78

Prev Close $14.71

Day Range $14.03 – $14.82

52W Range $6.96 – $16.93

Market Cap $799.38M

Beta 2.91

EPS (TTM) $-2.76

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-12-11
Shares Out.	52,280,000
Website	4dmoleculartherapeutics.com/ ↗
Phone	15105052680
Employees	196
Revenue	$3.8M
Gross Profit	$3.8M
Net Income	-$72.9M
Free Cash Flow	-$156.2M
Total Assets	$492.6M
Total Liabilities	$85.0M
Equity	$407.7M

About 4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

4D Molecular Therapeutics Inc is a publicly traded company under the ticker symbol FDMT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.